UBXG News

Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings. Phase 1 oncology biotech Boundless Bio (BOLD) raised $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Its lead ecDTx, BBI-355, is a novel, oral, selective...read more

U-BX Technology, which provides a variety of services to insurance companies in China, raised $10 million by offering 2 million shares at $5, as expected. U-BX Technology's business consists of digital promotion services, risk assessment services, and value-added bundled benefits. Utilizing its proprietary algorithmic model, the company is able to generate individualized risk...read more

U-BX Technology, which provides a variety of services to insurance companies in China, lowered the proposed deal size for its upcoming IPO on Friday. In its latest filing, the company also disclosed financials for the fiscal year ended June 30, 2023, and replaced sole bookrunner Boustead Securities with Prime Number Capital. The Beijing, China-based company now plans to raise $10...read more

U-BX Technology, which provides a variety of services to insurance companies in China, set a proposed price for its upcoming IPO on Monday. The Beijing, China-based company now plans to raise $25 million by offering 5 million shares at $5. The company had previously filed to offer 5 million shares at a range of $4 to $5. At the proposed price, U-BX Technology will raise 11% more in...read more